AbbVie may be setting its sights on 2026, but analysts are already smitten with its present-day promise. Cantor Fitzgerald ...

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...

Ten Mayo men were part of the AbbVie squad that captured the All-Ireland Intermediate Interfirms title, defeating Boston ...

Scotiabank analyst Louise Chen initiated coverage with a Buy rating on AbbVie (ABBV – Research Report) yesterday and set a price target of ...

Shares of AbbVie Inc. ABBV slipped 1.64% to $170.16 Monday, on what proved to be an all-around dismal trading session for the ...

Class will soon be in session at Allergan Aesthetics.Allergan Medical Institute (AMI), the educational arm of Allergan, is ...

Collaboration aims to leverage the ISPOR UAE Chapter’s network and knowledge in HEOR and AbbVie’s scientific expertise to ...

We recently published a list of Jim Cramer’s Game Plan for Next Week: 25 Stocks in Focus. In this article, we are going to ...

Abbvie (Sligo) won their first ever All-Ireland Inter-Firms title after defeating Boston Scientific (Cork) 1-11 to 1-6 in the All-Ireland Intermediate Football Final last Friday evening in Bishopstown ...

US drug maker AbbVie has launched its key leukemia drug, Venetoclax, in India, marking its entry into the country's oncology ...

AbbVie expands global oncology footprint in India with launch of Venetoclax: Our Bureau, Bengaluru Monday, April 21, 2025, 16:40 Hrs [IST] AbbVie, a global biopharmaceutical major ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...